Fulgent Genetics: From Genetic Code To Cancer Cure - Why I Assign A Hold Rating [Seeking Alpha]
Fulgent Genetics, Inc. (FLGT)
Last fulgent genetics, inc. earnings: 3/10 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fulgentgenetics.com
Company Research
Source: Seeking Alpha
FLGT's diagnostics business leads with rapid genome tests and expanded Beacon carrier screening, solidifying its market leadership and supporting continued revenue growth. The pipeline includes FID-007 and FID-022 cancer therapies, with FID-007 showing a 51% response rate in Phase II, highlighting future growth potential. But this is years before going commercial. FLGT boasts a robust $788M cash position, enabling sustained R&D investment and strategic acquisitions, while its synergistic model offers a competitive edge. PeopleImages/iStock via Getty Images Fulgent Genetics, Inc. (NASDAQ: FLGT ) stock is trading at its 52-week highs after a solid double-digit gain over the past month. This significant growth followed its release of exciting Q3 numbers earlier in November which saw This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within t
Show less
Read more
Impact Snapshot
Event Time:
FLGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FLGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FLGT alerts
High impacting Fulgent Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
FLGT
News
- Fulgent Genetics (NASDAQ:FLGT) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
- Fulgent Genetics to Acquire Bako Diagnostics Assets and StrataDx for $55.5 Million [Los Angeles Times (CA)]Los Angeles Times
- Fulgent Genetics to buy Bako Diagnostics assets and StrataDx [Yahoo! Finance]Yahoo! Finance
- Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx [Yahoo! Finance]Yahoo! Finance
- Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDxBusiness Wire
FLGT
Earnings
- 11/7/25 - Beat
FLGT
Analyst Actions
- 11/14/25 - Raymond James Financial, Inc.
FLGT
Sec Filings
- 12/22/25 - Form 8-K
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- FLGT's page on the SEC website